文献速递冠心病

即时全血高敏肌钙蛋白I检测用于低风险急性心肌梗死排除

Single High-Sensitivity Point-of-Care Whole-Blood Cardiac Troponin I Measurement to Rule Out Acute Myocardial Infarction at Low Risk.
PubMed 文献 · Circulation · 2022-10-31

研究基于两项前瞻性观察队列,在急诊疑似急性冠脉综合征患者中衍生并验证即时全血高敏肌钙蛋白I(hs-cTnI)阈值(<4 ng/L),用于排除急性心肌梗死。衍生队列(SEIGE,1086例,8.1%心梗)敏感性98.9%、阴性预测值99.5%;验证队列(SAMIE,1486例,5.5%心梗)敏感性98.8%、阴性预测值99.8%。该检测可快速安全排除心梗并可能加速急诊离院。

要点

  • 即时全血hs-cTnI<4 ng/L可安全排除急性心梗。
  • 衍生队列敏感性98.9%、阴性预测值99.5%。
  • 验证队列敏感性98.8%、阴性预测值99.8%。

核心结论

  • 即时全血hs-cTnI检测可及、快速且安全地排除急性心肌梗死,可能加速急诊离院。

研究设计与样本

  • 两项前瞻性观察研究纳入急诊疑似急性冠脉综合征连续患者,衍生队列(SEIGE)1086例,验证队列(SAMIE)1486例。

主要发现

  • 衍生队列中8.1%发生心梗,验证队列中5.5%发生心梗。
  • 衍生全血即时hs-cTnI<4 ng/L排除心梗的敏感性98.9%(95%CI 93.8%-100%),阴性预测值99.5%(95%CI 97.2%-100%)。
  • 验证队列敏感性98.8%(95%CI 93.3%-100%),阴性预测值99.8%(95%CI 99.1%-100%)。
  • 衍生与验证队列分别有17.8%和41.8%被定义为低风险可离院。
  • 30天不良心脏事件在SEIGE为0.1%(n=1),在SAMIE为0.8%(n=5)。

关键数值与推荐

  • 全血即时hs-cTnI(Atellica VTLi)阈值<4 ng/L用于排除指数心梗,衍生队列敏感性98.9%、阴性预测值99.5%。
  • 验证队列采用血浆检测,敏感性98.8%、阴性预测值99.8%。

临床怎么用

  • 急诊疑似急性冠脉综合征患者就诊时可用即时全血hs-cTnI<4 ng/L快速识别低风险心梗患者,考虑早期离院。

局限性

  • 衍生与验证队列分别在美国和澳大利亚进行,阈值基于全血衍生但验证使用血浆。
  • 低风险离院比例在衍生队列为17.8%,验证队列为41.8%,存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-sensitivity cardiac troponin (hs-cTn) laboratory assays are used to rule out myocardial infarction (MI) on presentation, but prolonged result turnaround times can delay patient management. Our primary aim was to identify patients at low risk of index MI using a rapid point-of-care (POC) whole-blood hs-cTnI assay at presentation with potential early patient discharge. METHODS: Consecutive patients presenting to the emergency department from 2 prospective observational studies with suspected acute coronary syndrome were enrolled. A POC hs-cTnI assay (Atellica VTLi) threshold using whole blood at presentation, which resulted in a negative predictive value of ≥99.5% and sensitivity of >99% for index MI, was derived (SEIGE [Safe Emergency Department Discharge Rate]) and validated with plasma (SAMIE [Suspected Acute Myocardial Infarction in Emergency]). Event adjudications were established with hs-cTnI assay results from routine clinical care. The primary outcome was MI at 30 days. RESULTS: A total of 1086 patients (8.1% with MI) were enrolled in a US derivation cohort (SEIGE) and 1486 (5.5% MI) in an Australian validation cohort (SAMIE). A derivation whole-blood POC hs-cTnI concentration of <4 ng/L provided a sensitivity of 98.9% (95% CI, 93.8%-100%) and negative predictive value of 99.5% (95% CI, 97.2%-100%) for ruling out MI. In the validation cohort, the sensitivity was 98.8% (95% CI, 93.3%-100%), and negative predictive value was 99.8% (95% CI, 99.1%-100%); 17.8% and 41.8%, respectively, were defined as low risk for discharge. The 30-day adverse cardiac events were 0.1% (n=1) for SEIGE and 0.8% (n=5) for SAMIE. CONCLUSIONS: A POC whole-blood hs-cTnI assay permits accessible, rapid, and safe exclusion of MI and may expedite discharge from the emergency department. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT04772157. URL: https://www.australianclinicaltrials.gov.au/anzctr_feed/form; Unique identifier: 12621000053820.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Apple, Smith, Greenslade, et al. Single High-Sensitivity Point-of-Care Whole-Blood Cardiac Troponin I Measurement to Rule Out Acute Myocardial Infarction at Low Risk. Circulation. 2022. PMID: 36314160. doi:10.1161/CIRCULATIONAHA.122.061148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。